Results 261 to 270 of about 40,704 (273)
CYP2C19 genetics in fatal carisoprodol intoxications [PDF]
European Journal of Clinical Pharmacology, 2012 Carisoprodol, a frequently used muscle relaxant, can cause potentially fatal intoxications. Conversion to its active metabolite meprobamate is almost solely mediated by cytochrome P450 2C19 (CYP2C19), and mutations in this enzyme could have significant effects on serum concentrations.
Jørg Mørland +6 more
openaire +2 more sources
Some of the next articles are maybe not open access.
Related searches:
Related searches:
Genetic polymorphism of CYP2C19 in Maharashtrian population
European Journal of Epidemiology, 2007Inter-individual variability in drug response is well known. Genetic polymorphism in genes encoding drug-metabolizing enzymes results in variation in drug metabolism and in turn drug response. The cytochrome P450 enzymes (CYP) play a central role in the metabolism of many therapeutic agents.
Yashendra Arya +6 more
openaire +3 more sources
Clinical and Experimental Pharmacology and Physiology, 2013
Summary The purpose of the present study was to examine whether cytochrome P450 2C19 (CYP2C19) in carriers of the CYP2C19*17 allele is inhibited in vivo by oral contraceptives (OC). Retrospective CYP2C19 phenotyping according to omeprazole : 5‐OH‐omeprazole molar 3 h plasma metabolic ratios (MR) from a population (n = 222) genotyped as CYP2C19*1/*1,
Pedersen, Rasmus Steen +2 more
openaire +4 more sources
Summary The purpose of the present study was to examine whether cytochrome P450 2C19 (CYP2C19) in carriers of the CYP2C19*17 allele is inhibited in vivo by oral contraceptives (OC). Retrospective CYP2C19 phenotyping according to omeprazole : 5‐OH‐omeprazole molar 3 h plasma metabolic ratios (MR) from a population (n = 222) genotyped as CYP2C19*1/*1,
Pedersen, Rasmus Steen +2 more
openaire +4 more sources
2015
This chapter discusses the genetics, metabolic actions, substrates, inducers, and inhibitors of cytochrome P450 2C9.
Randal O. Dull +2 more
openaire +2 more sources
This chapter discusses the genetics, metabolic actions, substrates, inducers, and inhibitors of cytochrome P450 2C9.
Randal O. Dull +2 more
openaire +2 more sources
Fluvoxamine inhibits the CYP2C19-catalyzed bioactivation of chloroguanide*
Clinical Pharmacology & Therapeutics, 1997To investigate the interaction between fluvoxamine and chloroguanide (INN, proguanil) to confirm that fluvoxamine inhibits CYP2C19.The study was carried out with a randomized, in vivo, crossover design. Six volunteers were extensive metabolizers of the S-mephenytoin oxidation polymorphism, and six volunteers were poor metabolizers.
Jeppesen, Unni +2 more
openaire +4 more sources
Prevalence of CYP2C19 polymorphisms in the Lebanese population
Molecular Biology Reports, 2011Clopidogrel is one of the most commonly prescribed drugs, as its combination with low-dose aspirin is the recommended oral anti-platelet therapy, to prevent ischaemic events following coronary syndromes or stent placement. Numerous recent studies have shown that polymorphisms in the gene encoding the cytochrome P450 (CYP450) 2C19 enzyme (CYP2C19 ...
Sose Keleshian +5 more
openaire +3 more sources
The Metabolism of Clopidogrel: CYP2C19 Is a Minor Pathway
The Journal of Clinical Pharmacology, 2016AbstractThe major metabolic pathway of clopidogrel is conversion to carboxylic acid by an esterase (CES1), forming clopidogrelic acid (SR26334) that is inactive. There is agreement on the structure of the active metabolite; however, there are differing views about the mechanism of its formation.
openaire +3 more sources
CYP2C19*2 and CYP2C19*3 allelomorphism in Turkish population
International Journal of Cardiology, 2017openaire +4 more sources